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Purpose
Further study delivery system of precipitation of micron-
sized particles of insoluble allergen in muscle for immu-
notherapy (IT) to PI urushiol and adapt it to treat allergy
to PN.
Background
At AAAAI 2010 we reported induction of tolerance in 2
patients highly allergic to PI with cumulative doses of
less than 1 mg urushiol administered IM in small
volumes of 95-100% ethanol. Sensitivity on a quantitative
patch test mirrors clinical response. Induction of complete
clinical tolerance to poison ivy urushiol has not been
reported in sensitized humans or animals with any other
vaccine delivery technique.
We believe the mechanism is rapid dilution of the
ethanol by tissue fluid precipitating urushiol in particles
of a size that is efficiently taken up by local antigen proces-
sing cells. We believe this is functionally similar to SQ IT
with antigen on a carrier of 2μ sepharose beads and of
IT by direct injection of vaccine into lymph nodes.
The same mechanism of T-regulatory cell tolerogenesis
is common to humoral and cell mediated immunity. We
propose to make allergoids of Ara h2 that are soluble in
ethanol but insoluble in water, and study the same vac-
cine delivery system in a mouse model of peanut allergy.
Methods
PI: A patient who responded to poison ivy vaccine but
lost tolerance by 12 months is scheduled for re-treatment
this fall. PN: Allergoids of Ara h2 are made either by
cross-linking with glutaraldehyde +/- formaldehyde or by
carbamylation of lysine residues with potassium cyanate.
Polymerization reduces solubility in water. There are
known and novel methods to further reduce solubility in
water and increase it in ethanol.
Results
PI: Four of 5 patients highly sensitive on a quantitative
poison ivy patch test achieved tolerance with cumulative
urushiol doses of 0.8 to 4 mg. Tolrance lastied 9-36+
months and was accompanied by 22 to 5000-fold reduc-
tion in patch test sensitivity. PN: Vaying parameters of
allergoid formation changes water solubility. We expect
to have additional data for both PI and PN by the time
of the meeting.
Conclusions
Precipitation of water-insoluble allergy vaccine from
ethanol injected IM is a novel method of IT, effective in
patients highly allergic to PI. We are trying to adapt the
same delivery system to allergoids of Ara h2 for allergy
to PN.
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